Despite the effectiveness of endocrine therapy, disease recurrence remains a significant challenge for patients with HR-positive/HER2-negative early breast cancer. Up to 20% of patients will experience relapse within 10 years of diagnosis. This activity explores the role of CDK4/6 inhibitors as adjuvant therapy for HR-positive/HER2-negative early breast cancer, criteria for identifying high-risk patients, and the safety and efficacy profiles of available agents.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 1515 W Cypress Creek Rd
Pricing
100% of listed courses are free
56 of 56 courses listed here are free.
Collected from the provider’s public pages
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Board review / self-assessment
- Credit · Up to 0.5 credits
- MOC · Up to 0.5 points
-
ReleasedJan 30, 2026
-
Last day to claim creditFeb 28, 2027 5 months left
-
National Comprehensive Cancer Network Case Challenge: Optimizing Adjuvant Therapy for a 39-Year-Old Premenopausal Woman With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
-
Medical Learning Institute, Inc. Oncologist Voices from the Frontline: Adjuvant CDK4/6 Therapy in HR+ HER2- Breast Cancer
-
Efficient CME, CME Outfitters, LLC Reshaping the Paradigm in Hormone Receptor Positive, HER2-negative Early Breast Cancer: How Next Generation SERDs May Challenge the Adjuvant Treatment Landscape
-
Kaplan Medical Education First- and Second-Line Treatment of Follicular Lymphoma With Bispecific Antibodies
-
Kaplan Medical Education Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma
-
Kaplan Medical Education Ublituximab Shows Better Outcomes of No Evidence of Disease Activity in Relapsing MS
